Want to see FR:ALBPS full AI Analyst Report?
ALBPS Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.22
Previous CloseN/A
Volume65.06K
Average Volume (3M)346.06K
Market Cap
€1.83M
Enterprise Value€6.92M
Total Cash (Recent Filing)€1.21M
Total Debt (Recent Filing)€7.77M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding119,786,090
10 Day Avg. Volume335,651
30 Day Avg. Volume346,065
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€2.00M
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage SpecializationSpecialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.
Improving Loss And Cash-burn TrendsMaterial narrowing of losses and reduced cash outflows in 2024 signals better cost control and operational discipline. Sustained improvements enhance runway and lower near-term financing pressure, increasing the company’s ability to reach clinical inflection points before further dilution.
Partial Debt Reduction Since 2022Measured reduction in debt improves balance-sheet flexibility and reduces leverage risk versus earlier peaks. Lower gross debt enhances negotiating leverage with partners and lenders and modestly reduces fixed financing costs, helping preserve cash for critical R&D activities.
Bears Say
No Revenue Over Multiple YearsAbsence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.
Deeply Negative Shareholders' EquityDeep negative equity signals cumulative losses that impair solvency metrics and limit traditional financing options. Structural equity deficits can force dilutive recapitalizations or restrictive creditor terms, reducing strategic flexibility over the medium term.
Persistent Cash Burn And Funding DependenceConsistent negative operating and free cash flow create ongoing dependency on external financing. Even with 2024 improvement, the structural need for capital raises heightens dilution risk, constrains multi-year planning, and may delay or complicate advancement of pivotal clinical programs.
Biophytis SA News
ALBPS FAQ
What was Biophytis SA’s price range in the past 12 months?
Biophytis SA lowest stock price was €0.01 and its highest was €0.22 in the past 12 months.
What is Biophytis SA’s market cap?
Biophytis SA’s market cap is €1.83M.
When is Biophytis SA’s upcoming earnings report date?
Biophytis SA’s upcoming earnings report date is Sep 11, 2026 which is in 68 days.
How were Biophytis SA’s earnings last quarter?
Currently, no data Available
Is Biophytis SA overvalued?
According to Wall Street analysts Biophytis SA’s price is currently Overvalued.
Does Biophytis SA pay dividends?
Biophytis SA does not currently pay dividends.
What is Biophytis SA’s EPS estimate?
Biophytis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biophytis SA have?
Biophytis SA has 119,786,090 shares outstanding.
What happened to Biophytis SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biophytis SA?
Currently, no hedge funds are holding shares in FR:ALBPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biophytis SA
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.